Schmitt D, Levy R, Carroll B
ToxStrategies, Inc, Naperville, IL, USA
Primus Pharmaceuticals, Inc, Scottsdale, AZ, USA.
Int J Toxicol. 2016 Sep;35(5):558-67. doi: 10.1177/1091581816655303. Epub 2016 Jun 29.
In a subchronic toxicity study, administration of β-caryophyllene (BCP) oil by oral gavage to Wistar rats at dosages of 0, 150, 450, or 700 mg/kg/d for 90 days, including a 21-day recovery period, did not produce any significant toxicologic manifestations. The study design also included a 28-day interim sacrifice in the control and high-dose groups. The BCP oil test article was well tolerated as evidenced by the absence of major treatment-related changes in the general condition and appearance of the rats, neurobehavioral end points, growth, feed and water intake, ophthalmoscopic examinations, routine hematology and clinical chemistry parameters, urinalysis, and necropsy findings. The no observed adverse effect level was the highest dosage level administered of 700 mg/kg body weight/d for both male and female rats. The study was conducted as part of an investigation to examine the safety of BCP oil for its proposed use in medical food products.
在一项亚慢性毒性研究中,以0、150、450或700毫克/千克/天的剂量对Wistar大鼠进行为期90天的β-石竹烯(BCP)油灌胃给药,包括21天的恢复期,未产生任何明显的毒理学表现。该研究设计还包括在对照组和高剂量组进行为期28天的中期处死。BCP油受试物耐受性良好,大鼠的一般状况、外观、神经行为终点、生长、饲料和水摄入量、眼科检查、常规血液学和临床化学参数、尿液分析以及尸检结果均未出现与主要治疗相关的变化,即为证据。未观察到不良影响水平为雄性和雌性大鼠给药的最高剂量水平700毫克/千克体重/天。该研究是对BCP油拟用于医疗食品的安全性进行调查的一部分。